Search Submit Your Manuscript

Become A Member

  1. Home
  2. June 2021
  3. 22. Comparative Analysis for Reduction in A1c in Dapagliflozin Versus Glimepiride Monotherapy in Non-Obese Type 2 Diabetic Patients
Article Image
Admin

22. Comparative Analysis for Reduction in A1c in Dapagliflozin Versus Glimepiride Monotherapy in Non-Obese Type 2 Diabetic Patients

Muhammad Kamran Yousuf1, Mehr Fatima1, M.Sajid Abbas Jaffri1, Sadaf Haris1, Khalid Mustafa1 and Shahid Mustafa Memon2

ABSTRACT

Objective: To compare the efficacy and safety profile of dapagliflozin and glimepiride in type 2 diabetic non-obese patients.

Study Design: Randomized controlled trial study.

Place and Duration of Study: This study was conducted at the National Medical Center, Karachi from June 2019- December 2019.

Materials and Methods: A total of 200 diabetic patients had body mass index ≥ 28- ≤29.9 Kg/m2, body fat percentage ≥ 21- ≤31 in female, and ≥ 14 - ≤ 24 in male, baseline fasting blood sugar ≥ 126 mg/dL and glycated haemoglobin between ≥ 7.5 - ≤10% were recruited in the study. All the eligible patients were divided into two groups: dapagliflozin 10 mg and glimepiride 04 mg. The endpoint assessment included change of fasting plasma glucose (FPG), A1c, liver function test, renal function test, lipid profile and urinalysis. The analysis of the data performed by using statistical package of social sciences (SPSS) version 25.

Results: Both combination therapy led significant reductions in FPG and A1c levels as compared with baseline at 12th week. The monotherapy of dapagliflozin comparatively improve more level of A1c at short time than other intervention. Both of these therapies were shown safe levels of lipid profile, liver function test, renal function test and urinalysis among groups. None of the incidence of hypoglycemia, and urinary and genital tract infection were reported during the entire period of the study.

Conclusion: The treatment with dapagliflozin or glimepiride was generally well tolerated and effective for the improvement of glycemia in T2D patients. Dapagliflozin monotherapy with metformin relatively more effective in reducing FPG and A1c even in short time.

Key Words: Dapagliflozin, Glycemia, Glimepride, Obese, Type 2 diabetes mellitus

Citation of article: Yousuf MK, Fatima M, Jaffri MSA, Haris S, Mustafa K, Memon SM. Comparative Analysis for Reduction in A1c in Dapagliflozin Versus Glimepiride Monotherapy in Non-Obese Type 2 Diabetic Patients. Med Forum 2021;32(6):87-92.